PMID- 11132992
OWN - NLM
STAT- MEDLINE
DCOM- 20010111
LR  - 20170214
IS  - 0003-3197 (Print)
IS  - 0003-3197 (Linking)
VI  - 51
IP  - 12
DP  - 2000 Dec
TI  - Factors influencing efficacy of nitrate therapy for stable angina pectoris: a 
      multiple linear regression analysis.
PG  - 1007-12
AB  - In an open-label self-controlled study of 1,350 patients with stable angina 
      pectoris (SAP), we previously demonstrated that 50 mg of isosorbide mononitrate 
      (ISMN) slow release formulation once daily not only provided a better antianginal 
      effect but also a better quality of life (QOL) than did the daily administration 
      of multiple small doses of the compound. It is unknown whether certain patient 
      characteristics contribute to this benefit. The objective of this article was to 
      determine what independent factors contribute to this benefit. Multiple linear 
      regression analysis was performed on the data from these 1,350 patients. Quality 
      of life was assessed by the Marquis QOL-questionnaire for patients with angina 
      and included the domains of immobility, pain, and psychological distress. For the 
      purpose of this study, overall QOL was calculated as the pooled sums of the 
      domain scores and expressed as mean scores on an ordinal scale of 10. Age did not 
      influence the beneficial effect of nitrate therapy on QOL. Neither did gender, 
      rhythmic disturbances, peripheral artery disease, or the concomitant use of 
      calcium channel blockers or beta blockers. New York Heart Association (NYHA) 
      angina classification was an independent variable: patients with a NYHA class I 
      or II benefited less than did patients with NYHA III or IV (p = 0.02). Obese 
      patients as well as hypertensive patients benefited less (p = 0.04 and 0.02), and 
      smokers tended to benefit less also (p = 0.08). In contrast, hypercholesterolemia 
      and diabetes mellitus improved the beneficial effect of nitrates on QOL (p = 0.03 
      and 0.05). The authors conclude that patients with coronary artery disease (CAD) 
      and concomitant diabetes mellitus or hypercholesterolemia, a category 
      particularly prone to early endothelial dysfunction and thus dysfunctional 
      endogenous nitric oxide (NO) production, may benefit more from NO-donor therapy 
      than patients without such concomitant conditions.
FAU - Jansen, R
AU  - Jansen R
AD  - Academic Hospital, Groningen, The Netherlands.
FAU - Niemeyer, M G
AU  - Niemeyer MG
FAU - Cleophas, T J
AU  - Cleophas TJ
FAU - Zwinderman, A H
AU  - Zwinderman AH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Nitric Oxide Donors)
RN  - 0 (Vasodilator Agents)
RN  - IA7306519N (Isosorbide Dinitrate)
RN  - LX1OH63030 (isosorbide-5-mononitrate)
SB  - IM
MH  - Angina Pectoris/complications/*drug therapy
MH  - Coronary Disease/complications
MH  - Delayed-Action Preparations
MH  - Diabetes Complications
MH  - Drug Administration Schedule
MH  - Humans
MH  - Hypercholesterolemia/complications
MH  - Isosorbide Dinitrate/*administration & dosage/*analogs & derivatives
MH  - Linear Models
MH  - Nitric Oxide Donors/*administration & dosage
MH  - Quality of Life
MH  - Treatment Outcome
MH  - Vasodilator Agents/*administration & dosage
EDAT- 2001/01/02 11:00
MHDA- 2001/02/28 10:01
CRDT- 2001/01/02 11:00
PHST- 2001/01/02 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2001/01/02 11:00 [entrez]
AID - 10.1177/000331970005101205 [doi]
PST - ppublish
SO  - Angiology. 2000 Dec;51(12):1007-12. doi: 10.1177/000331970005101205.